Introduction
============

Hepatocellular carcinoma (HCC) is the fourth most prevalent human malignancy and the third cause of cancer-related deaths in China.[@b1-cmar-11-877] In 2015, it is estimated that there are 466,100 new cases and 422,100 deaths due to this disease.[@b1-cmar-11-877] Although patients with HCC can be managed with a series of therapeutic methods (including surgical resection, adjuvant chemotherapy, radiotherapy, and liver transplantation), the overall 5-year survival rate still remains poor (less than 20%).[@b2-cmar-11-877] Epidemiological studies have shown that chronic hepatitis B virus (HBV) infection is the predominant risk factor for the development, metastasis, and recurrence of HCC, accounting for about 80% of all HCC in China.[@b3-cmar-11-877]-[@b5-cmar-11-877] Thus, it is necessary to further investigate the molecular mechanisms of HBV-related HCC in order to screen novel prognostic biomarkers and develop effective therapeutic strategies.

Recently, there have studies to indicate that the abnormal expression of lncRNAs, a class of noncoding RNAs longer than 200 nt in length, is associated with the development of various cancers, including HBV-related HCC.[@b6-cmar-11-877],[@b7-cmar-11-877] For example, Zuo et al found that lncRNA AX800134 was upregulated in HBV-positive HCC compared with HBV-negative HCC. Silencing AX800134 with siRNA interference significantly suppressed the growth and invasion but enhanced spontaneous apoptosis of HBx-expressing HepG2 cells.[@b8-cmar-11-877] The study of Lv et al revealed that the expression of lncRNA DREH was frequently downregulated in HBV-associated HCC tissues in comparison with adjacent noncancerous hepatic tissues. Inhibition of DREH expression by HBx remarkably promoted the proliferation of HCC cells in vitro and in vivo.[@b9-cmar-11-877] Yang et al identified that lncRNA-HEIH was highly expressed in liver samples from patients with HBV-related HCC. The expression level of lncRNA-HEIH in HBV-related HCC was significantly associated with recurrence and was an independent prognostic factor for survival.[@b10-cmar-11-877] However, the mechanisms of lncRNAs in HBV-related HCC remain not fully elucidated.

Previously, emerging evidence has demonstrated that lncRNAs may function as molecular sponges for a miRNA through their miRNAs response elements (MREs) and thereby influence the translation inhibition or mRNA degradation of the transcript on the targets by the respective miRNAs, which is proposed as ceRNA hypothesis.[@b11-cmar-11-877] Accumulating data also indicated that this regulatory action plays important roles in HCC development.[@b12-cmar-11-877],[@b13-cmar-11-877] For example, Lv et al[@b14-cmar-11-877] showed that lnRNA Unigene56159 promoted the migration and invasion of HCC cells by acting as a ceRNA for miR-140-5p to de-repress the expression of Slug and induce the epithelial--mesenchymal transition (EMT). Mo et al[@b15-cmar-11-877] observed the upregulated LINC01287 competitively bound to miR-298 and increased the expression of its target gene *STAT3* to promote EMT and invasion of HCC cells. lncRNA n335586 was also reported to promote EMT of HCC cells and then migration as well as invasion through facilitating the expression of its host gene creatine kinase, mitochondrial 1A (*CKMT1A*) by competitively binding miR-924.[@b16-cmar-11-877] lncRNA SNHG12 functioned as an oncogene to accelerate tumorigenesis and metastasis of HCC cells by sponging miR-199a/b-5p, which resulted in the high expression of *MLK3* (mitogen-activated protein kinase kinase kinase 11) and activated the NF-κB pathway.[@b17-cmar-11-877] HCAL directly interacted with and functioned as a sponge for miR-15a, miR-196a, and miR-196b to modulate lysosomal protein transmembrane 4 beta (*LAPTM4B*) expression in HCC.[@b18-cmar-11-877] However, studies performed to investigate the ceRNA mechanisms of lncRNAs for HBV-related HCC were rare.[@b14-cmar-11-877],[@b16-cmar-11-877]

The goal of this study was to identify novel lncRNA-- miRNA--mRNA interaction axes for explaining the development of HBV-associated HCC by constructing a ceRNA regulatory network using sequencing data collected from a public database. Also, the prognosis performance of related lncRNAs, miRNA, and mRNAs was also validated by utilizing The Cancer Genome Atlas (TCGA) datasets. We believe that our study may provide novel prognostic biomarkers and therapeutic targets for HBV-associated HCC.

Methods
=======

Data collection and preprocessing
---------------------------------

Two datasets under accession numbers GSE77509[@b19-cmar-11-877] and GSE76903[@b19-cmar-11-877] were retrieved from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>). These two datasets examined the RNA expression profiling and noncoding (miRNA) expression profiling in 20 primary tumors and 20 matched adjacent normal tissues from patients with HBV-induced HCC by high-throughput sequencing via HiSeq 2500 System (Illumina, San Diego, CA, USA). The samples were the same for the two datasets. The fragment per kilobase per million mapped reads (FPKM) expression data in TXT files were downloaded and preprocessed by removing low abundance genes with an FPKM of \<1. The lncRNA and mRNA genes in RNA expression profiling were annotated based on the Ensembl Gene ID and HUGO Gene Nomenclature Committee (HGNC; <http://www.genenames.org/>).[@b20-cmar-11-877]

Differentially expressed RNA analysis
-------------------------------------

The differentially expressed genes (DEGs), differentially expressed lncRNAs (DELs), and differentially expressed miRNAs (DEMs) between primary tumors and adjacent normal tissues were identified using the EdgeR package of R software (Version 3.22.3; <http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>).[@b21-cmar-11-877] *P*-value was adjusted to false discovery rate (FDR) with multitest package (Version 2.36.0; <http://bioconductor.org/packages/release/bioc/html/multtest.html>).[@b22-cmar-11-877] The FDR of \<0.05 and \|logFC(fold change)\| \>1 were set as the statistical threshold value. Hierarchical cluster heatmap representing the expression intensity and direction of DEGs, DELs, and DEMs was generated using the pheatmap R package (Version: 1.0.8; <https://cran.r-project>. org/web/packages/pheatmap) based on Euclidean distance.

Protein--protein interaction (PPI) network
------------------------------------------

The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; Version 10.0; <http://stringdb.org/>) database[@b23-cmar-11-877] was used to assess the direct and indirect correlations between DEGs. The screened interaction pairs among DEGs were used to construct the PPI network with the Cytoscape software (Version 3.6.1; [www.cytoscape.org/](http://www.cytoscape.org/)).[@b24-cmar-11-877] The topological features of the PPI network, consisting of degree (the number of edges \[interactions\] of a node protein\]), betweenness centrality (BC; the number of shortest paths that run through a node), closeness centrality (CC; the average length of the shortest paths to access all other proteins in the network), and average path length (APL; the average of distances between all pairs of nodes), were then calculated using the CytoNCA plugin in cytoscape software (<http://apps.cytoscape.org/apps/cytonca>)[@b25-cmar-11-877] to determine which genes were hub nodes. Functionally related clusters with well-interconnected genes were further identified from the PPI network using the Molecular Complex Detection (MCODE; Version: 1.4.2, <http://apps.cytoscape.org/apps/mcode>) algorithm[@b26-cmar-11-877] with default scoring options. Modules with score \>4 and node \>6 were considered to be significant.

Function enrichment analysis
----------------------------

Gene Ontology (GO) Biological Process term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs were conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (Version 6.8; <http://david.abcc.ncifcrf>. gov)[@b27-cmar-11-877] and BinGO[@b28-cmar-11-877] plugin in Cytoscape to predict their underlying functions. Statistical significance was defined as FDR \<0.05.

lncRNA--miRNA--mRNA ceRNA regulatory network construction
---------------------------------------------------------

The miRcode database (Version 11; <http://www.mircode.org/>)[@b29-cmar-11-877] was used to screen the interaction relationships between DELs and DEMs, and then, the DELs--DEMs interaction network was constructed using the Cytoscape software (Version 3.6.1; [www.cytoscape.org/](http://www.cytoscape.org/)).[@b24-cmar-11-877] The target genes of DEMs in the DELs--DEMs interaction network were predicted using the miRwalk database (Version 2.0; <http://www.zmf.umm>. uni-heidelberg.de/apps/zmf/mirwalk2),[@b30-cmar-11-877] which were then overlapped with the DEGs to obtain the DELs--DEMs--DEGs regulatory relationships. The negative interaction pairs between DEMs and DEGs/DELs were integrated to construct the DELs--DEMs--DEGs ceRNA network using the Cytoscape software (Version 3.6.1; [www.cytoscape.org/](http://www.cytoscape.org/)).[@b24-cmar-11-877]

Furthermore, all known HCC-related pathways were downloaded from Comparative Toxicogenomics Database (CTD; <http://ctd.mdibl.org/>),[@b31-cmar-11-877] which was then overlapped with the pathways enriched by the genes in the ceRNA network to obtain potentially HCC-related ceRNA network.

Prognosis values of DELs, DEMs, and DEGs in ceRNA network
---------------------------------------------------------

The miRNAs and mRNAs expression profile data of HCC were also collected from TCGA (<https://gdc-portal.nci.nih>. gov/) database, with only the HBV samples having survival information, included. Univariate Cox regression analysis was performed to screen prognosis-related DELs, DEMs, and DEGs using the survival package (Version 2.40.1; <https://cran.r-project>. org/package=survival). The samples were then classified into a low-expression group (\< median) and a high-expression group (\> median) based on the expression of each prognosis-related DEL, DEM, and DEG. The Kaplan--Meier (KM) method with the log-rank test was employed to compare the overall survival (OS) and recurrence-free survival (RFS) between the high- and low-expression groups through the GraphPad Prism software (Version 5; GraphPad Software, Inc., La Jolla, CA, USA). *P*\<0.05 was considered to be statistically significant.

Validation of expressions of crucial DELs, DEMs, and DEGs in ceRNA network
--------------------------------------------------------------------------

The expressions of crucial DELs, DEMs, and DEGs were also validated in TCGA dataset and other microarray datasets that detected the mRNA (GSE121248: 70 vs 37; GSE94660[@b32-cmar-11-877]: 21 vs 21; GSE25599[@b33-cmar-11-877]: 10 vs 21 normal), miRNA (GSE69580: 5 vs 5), and lncRNA (GSE27462[@b34-cmar-11-877]: 5 vs 5) expression profile between tumor and matched adjacent tissues from HBV-- HCC patients. All microarray datasets were also collected from the GEO database. The expression difference was tested by *t*-test. *P*\<0.05 was set as statistical significance.

Results
=======

Differential expression analysis
--------------------------------

A total of 133 lncRNAs, 18,628 protein-coding mRNAs, and 2,578 miRNAs were annotated in mRNA-seq and miRNA-seq data. After removing the low abundance genes with an FPKM of \<1, 80 lncRNAs, 16,169 protein-coding mRNAs, and 874 miRNAs were left for differential expression analysis. Based on the given threshold (FDR \<0.05 and \|logFC\| \>1), a total of 43 DELs (14 downregulated and 29 upregulated), 83 DEMs (10 downregulated and 73 upregulated), and 1,187 DEGs (650 downregulated and 537 upregulated) were identified between adjacent normal tissues and primary tumors ([Table 1](#t1-cmar-11-877){ref-type="table"}). The heat map analysis showed that the samples with similar features tended to be clustered according to the expressions of DELs ([Figure 1A](#f1-cmar-11-877){ref-type="fig"}), DEMs ([Figure 1B](#f1-cmar-11-877){ref-type="fig"}), and DEGs ([Figure 1C](#f1-cmar-11-877){ref-type="fig"}).

Function enrichment for DEGs
----------------------------

The upregulated and downregulated DEGs were subjected to the DAVID to predict their functions. The results indicated that 16 GO biological process terms were obtained for the upregulated genes, mainly involving cell cycle (ie, *E2F2, CDK1, CCNE1, BUB1, UBE2C*, and *CCNB1*), while 27 GO biological process terms were enriched for the downregulated genes, mainly involving inflammatory response (*PF4* and *CXCR1*) ([Table 2](#t2-cmar-11-877){ref-type="table"} and [Figure 2A](#f2-cmar-11-877){ref-type="fig"}). Furthermore, the KEGG pathway enrichment analysis was performed. In line with the GO enrichment results, the cell cycle (*E2F2, CDK1, CCNE1, BUB1*, and *CCNB1*) and p53 signaling pathway (*CDK1, CCNE1*, and *CCNB1*) were also obtained for the upregulated genes, while cytokine--cytokine receptor interaction was enriched for the downregulated genes (*PF4* and *CXCR1*) ([Table 3](#t3-cmar-11-877){ref-type="table"} and [Figure 2B](#f2-cmar-11-877){ref-type="fig"}).

PPI network construction
------------------------

Using the STRING database, 2,065 interaction relationship pairs (eg, BUB1--CDK1) were obtained between the 357 DEGs (182 downregulated and 175 upregulated), which were used for constructing a PPI network ([Figure 3](#f3-cmar-11-877){ref-type="fig"}). After calculating the topological features for each protein in PPI network, CCNB1, CDK1, G protein subunit gamma 4 (GNG4), UBE2C, G protein subunit gamma transducin 1 (GNGT1), kinesin family member 4A (KIF4A), PF4, and G protein subunit gamma 13 (GNG13) were found to be shared in four topological characteristics and ranked in the top 30, suggesting that they may be hub genes ([Table 4](#t4-cmar-11-877){ref-type="table"}).

Four significant functionally related modules ([Figure 4](#f4-cmar-11-877){ref-type="fig"}) were subsequently screened using the MCODE, among which the module 1 was the most significant with score =14.474 and node =38, followed by module 2 with score =13.152 and node =46. Also, GO analysis of genes in modules 1 and 2 with BinGO plugin of Cytoscape indicated that they were involved in mitotic cell cycle (*CCNB1, CDK1, BUB1*, and *UBE2C*) and cell surface receptor-linked signaling pathway (*PF4* and *CXCR1*) ([Table 5](#t5-cmar-11-877){ref-type="table"}).

CeRNA network construction
--------------------------

By searching the miRcode database, 14 DELs--DEMs interaction relationship pairs (including five DELs, all upregulated, and 10 DEMs, five upregulated and five down-regulated) were predicted, which were used for constructing the DELs--DEMs network. Subsequently, the target genes of these 10 DEMs were predicted with the miRwalk database. After removal of the positive--negative relationships between DEMs and DEGs, 113 DELs--DEMs interaction relationship pairs (including eight DEMs, three upregulated and five downregulated, and 82 DEGs, 67 upregulated and 15 downregulated) were left for constructing the DEMs--DEGs network. By integrating the DELs--DEMs network and DEMs--DEGs network, a DELs--DEMs--DEGs ceRNA network was established containing 95 nodes (five DELs, eight DEMs, and 82 DEGs) and 239 edges (14 DELs--DEMs, 113 DELs--DEGs, and 112 DEGs--DEGs) ([Figure 5](#f5-cmar-11-877){ref-type="fig"}).

Function enrichment analysis with DAVID showed the genes in the ceRNA network participated in four significant KEGG pathways, including cell cycle, p53 signaling pathway, neuroactive ligand--receptor interaction, and pathways in cancer ([Table 6](#t6-cmar-11-877){ref-type="table"}). By searching the CTD database with "Hepatocellular Carcinoma" as the keyword, 244 KEGG pathways were found to be associated with HCC. Among them, three were common with the enrichment results of the genes in the ceRNA network, including cell cycle (*CCNE1, E2F2*, and *CDK1*), p53 signaling pathway (*CCNE1* and *CDK1*), and pathways in cancer (*E2F2*). Thus, the DELs--DEMs--DEGs interaction relationship pairs associated with these three pathways were extracted to form the HCC-related ceRNA network ([Figure 6](#f6-cmar-11-877){ref-type="fig"}), in which four DELs (DSCR4, FAM182B, PRNT, and LINC00346), five DEMs (hsa-miR-199a-5p, hsa-miR-30a-5p, hsa-miR-125b-5, hsa-miR-10a-5p, and hsa-miR-133a-3p), and seven DEGs (*CDC6, CCNE1, CDK1, E2F2, BUB1, CCNB1*, and *SFN*) were involved.

Prognosis prediction for DELs, DEMs, and DEGs
---------------------------------------------

Ninety-eight HBV-related HCC samples, which have been used for mRNA and miRNA sequencing, were collected from TCGA database. Univariate Cox regression analysis was then used to screen OS- and RFS-related DELs, DEMs, and DEGs from HCC-related ceRNA network in these samples. The results showed that two DELs, four DEMs, and seven DEGs were significantly associated with OS, but only five DEGs were significantly associated with RFS ([Table 7](#t7-cmar-11-877){ref-type="table"}). KM curve was subsequently drawn according the expression level of each DEL, DEM, and DEG in the sequencing data. In line with the Cox regression analysis results, KM curve analysis also ([Figure 7](#f7-cmar-11-877){ref-type="fig"}) showed that two DELs (FAM182B and LINC00346), four DEMs (hsa-miR-30a-5p, hsa-miR-125b-5p, hsa-miR-10a-5p, and hsa-miR-133a-3p), and seven DEGs (*CDC6, CCNE1, CDK1, E2F2, BUB1, CCNB1*, and *SFN*) were significantly associated with OS but not PRNT (expression value =0 in TCGA data), DSCR4 (*P*=0.493), and hsa-miR-199a-5p (*P*=0.101). Also, all the relationships between their expressions and the prognosis results were in line with our expectation, that is, patients with the high expression of the DELs and DEGs (all were upregulated genes in HBV-related HCC) had the poor survival, while patients with the high expression of DEMs (all were downregulated genes in HBV-related HCC) possessed excellent survival. As shown in [Figure 8](#f8-cmar-11-877){ref-type="fig"}, KM curve analysis also showed that the highly expressed five DEGs (*CDC6, CDK1, BUB1, CCNB1*, and *SFN*) were significantly associated with RFS.

Further combination with their interaction relationships in the ceRNA network suggested that FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1* ceRNA axes were especially important for the development and prognosis of HBV-related HCC.

Validation of expressions of crucial DELs, DEMs, and DEGs in ceRNA network
--------------------------------------------------------------------------

The upregulation of LINC00346, *CDK1*, and *CCNE1* but the downregulation of miR-10a-5p and miR-125b-5p was also validated in other microarray datasets and TCGA data. FAM182B was not found to be differentially expressed in GSE27462 and TCGA data. *E2F2* was demonstrated to be differentially expressed in GSE94660, GSE25599, and TCGA data but not in GSE121248 ([Table 8](#t8-cmar-11-877){ref-type="table"}). These findings indicated that LINC00346-miR-10a-5p-*CDK1* ceRNA axis may be a potentially verifiable mechanism for HBV-related HCC.

Discussion
==========

In the present study, we identified FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1* ceRNA axes as important mechanisms for the development of HBV-related HCC. They were involved in HBV-related HCC by influencing cell cycle. Also, the genes in these two axes were significantly associated with the OS of patients. LINC00346-miR-10a-5p-*CDK1* may be especially crucial because *CDK1* was considered as a hub gene in the PPI network and was also associated with RFS as well as the expressions of all of them confirmed in other datasets.

Numerous studies have shown that HBV infection of hepatocytes promotes cell cycle progression by accelerating G1/S and G2/M transition and thus increases cell proliferation ability, ultimately inducing the development of HCC.[@b35-cmar-11-877],[@b36-cmar-11-877] It is well accepted that CCNE1 is a positive regulator of G1/S phase transition[@b37-cmar-11-877] and CCNB1 is required for G2/M transition and mitosis resumption by forming a maturation promoting factor with CKD1.[@b38-cmar-11-877] Transcriptional factor E2F2 can be activated by Cyclin-CDK enzymatic complex after phosphorylating the protein retinoblastoma (Rb), which promotes the transcription of E2F2 target genes to regulate the G1/S-phase transition.[@b39-cmar-11-877] Thus, *CCNE1, CCNB1, CKD1*, and *E2F2* genes are suggested to be upregulated in HBV-related HCC. These hypotheses have been demonstrated by previous studies. For example, Sung et al[@b40-cmar-11-877] used the RNA sequencing (RNA-seq) and Sanger sequencing to confirm that *CCNE1* gene was highly expressed in HBV integrated tumors compared with adjacent normal tissue. Chin et al[@b41-cmar-11-877] observed that delivery of a replication competent HBV genome into hepatocyte lines Huh7 and PMH induced the expression of CCNB1. Cheng et al[@b42-cmar-11-877] also used in vitro experiments to prove HBV persistently activated the CCNB1-CDK1 kinase in HCC cells. In line with these studies, our study also found *CCNE1, CCNB1*, and *CKD1* were upregulated in tumor samples of patients with HBV-related HCC and the high expression of them predicted poor prognosis. The CKD1 may be especially important because it was associated with both OS and RFS. Although there was a study to indicate E2F2 upregulation in HCC,[@b43-cmar-11-877] its relationship with HBV has not been investigated. Our study may be the first to reveal that HBV infection may trigger *E2F2* upregulation and lead to the development of HCC and poor prognosis for patients. miRNAs are the class of small RNAs (18--25 nucleotides) that downregulate target gene expressions via binding to the 3′-untranslated region (UTR). Thus, the upregulation of cell cycle-related genes may be attributed to the downregulation of miRNAs. In this study, we also investigated the DEMs between tumor and normal samples and predicted their interaction with target genes by the miRwalk database. Our results indicated that miR-10a-5p and miR-125b-5p could regulate *CDK1/CCNE1* and *E2F2*, respectively. There have studies to explore the miRNAs to regulate these target genes in HCC, such as miR-7/497/195-*CCNE1*,[@b44-cmar-11-877],[@b45-cmar-11-877] miR-582-5p-*CDK1*,[@b46-cmar-11-877] and miR-214/490-*E2F2*,[@b47-cmar-11-877],[@b48-cmar-11-877] but not focused on the relationships of our prediction. However, the studies on the expressions of miR-10a-5p and miR-125b-5p in HCC may indirectly illuminate their underlying negative relations. Zhu et al[@b49-cmar-11-877] identified the DEMs in seven paired specimens of HCC using the microarray technique and found that miR-10a-5p and miR-125b-5p were significantly downregulated. Over-expression of miR-10a[@b50-cmar-11-877] and miR-125b[@b51-cmar-11-877] was reported to suppress the metastasis of HCC cells in vivo. In line with these studies, our study also showed that miR-10a-5p and miR-125b-5p were downregulated in HBV-related HCC and high expression of them predicted excellent prognosis. lncRNAs are proposed to act as a ceRNA to involve in the regulation effects of miRNAs on the expression of target genes. Thus, the upregulation of cell cycle-related genes may also be attributed to the upregulation of lncRNAs that sponged the miRNAs. In this study, we also investigated the DELs between tumor and normal samples and predicted their interaction with miRNAs by the miRcode database. Our results indicated that upregulated FAM182B and LINC00346 may regulate cell cycle-related genes by interacting with miR-125b-5p and miR-10a-5p, resulting in poor prognosis. In line with our study, there has been a study to demonstrate that LINC00346 was upregulated in bladder cancer tissues compared to normal tissues. Knockdown of LINC00346 inhibited bladder cancer cell proliferation and migration and induced cell cycle arrest and cell apoptosis.[@b52-cmar-11-877] The high expression of LINC00346 was also found to be significantly associated with poor OS in HCC[@b53-cmar-11-877] and breast cancer samples.[@b54-cmar-11-877] Nevertheless, no studies were performed to investigate the interaction of LINC00346 with miRNAs. Also, any investigation related to FAM182B has not been found until now. These implied that our identified ceRNA axes (FAM182B-miR-125b-5p-*E2F2* and LINC00346-miR-10a-5p-*CDK1/CCNE1*) may be novel mechanisms for HBV-related HCC.

There were some limitations in this study. First, our study has preliminarily predicted that these ceRNA axes may be associated with the development of HBV-related HCC and some of them were confirmed in some other microarray datasets. Thus, further clinical, in vitro (dual luciferase reporter assay), and in vivo (loss of function) experiments are necessary to validate the expressions of controversial genes (such as FAM182B and *E2F2*) and regulatory relationships between DELs and DEMs as well as between DEMs and DEGs, and their roles for the proliferation, metastasis, and invasion of HBV infection hepatocytes. Second, there were no clinical data in our used datasets (GSE77509 and GSE76903) and, thus, we only preliminarily predicted the associations between prognosis (OS and RFS) and each of our identified DEL/DEM/DEG using TCGA data via univariate cox regression analysis. Whether these genes were independent biomarkers needed further clinical trials with multivariate Cox's model that integrated all the clinical information (such as HBV DNA level, liver function parameters, pathologic stage, pathologic node, and pathologic metastasis, grade, therapeutic strategies including hepatectomy, radiofrequency ablation, and solafenib)[@b55-cmar-11-877]--[@b57-cmar-11-877] and all DELs/DEMs/DEGs expression levels.

Conclusion
==========

The present study preliminarily indicates that FAM182B and LINC00346 may be novel prognostic biomarkers and therapeutic targets for HBV-associated HCC. They function as a ceRNA to sponge miR-125b-5p and miR-10a-5p to de-repress cell cycle-related genes (*E2F2, CDK1*, and *CCNE1*) and promote the cell growth of HCC cells.
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![Hierarchical clustering and heat map analysis of differentially expressed lncRNAs (**A**), miRNAs (**B**), and genes (**C**).\
**Notes:** Each row represents a sample, and each column represents an lncRNA, miRNA, or gene. High- or low-relative expression is displayed as a red or blue strip, respectively. Each group contained 20 different samples.\
**Abbreviations:** T, tumor; N, normal.](cmar-11-877Fig1){#f1-cmar-11-877}

![Function enrichment analyses for the differentially expressed genes.\
**Note:** (**A**) GO enrichment and (**B**) KEGG pathways enrichment.\
**Abbreviations:** GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](cmar-11-877Fig2){#f2-cmar-11-877}

![Protein and protein interaction network for the differentially expressed genes.\
**Notes:** Red, upregulated; green, downregulated. The larger size of node (protein) indicates the higher degree (interaction relationships) of it.\
**Abbreviation:** FC, fold change.](cmar-11-877Fig3){#f3-cmar-11-877}

![Modules extracted from the protein and protein interaction network.\
**Notes:** (**A**) module 1; (**B**) module 2; (**C**) module 3; and (**D**) module 4. Red, upregulated; green, downregulated. The larger size of node (protein) indicates the higher degree (interaction relationships) of it.](cmar-11-877Fig4){#f4-cmar-11-877}

![ceRNAs interaction network of lncRNA--miRNA--mRNA.\
**Notes:** Square nodes represent lncRNAs; triangle nodes represent miRNAs; circular nodes represent mRNAs. Red, upregulated; green, downregulated.\
**Abbreviation:** FC, fold change.](cmar-11-877Fig5){#f5-cmar-11-877}

![HCC-related ceRNAs interaction network of lncRNA--miRNA--mRNA.\
**Notes:** Square nodes represent circRNAs, triangle nodes represent miRNAs, circular nodes represent mRNAs, and rhombus nodes represent HCC pathways. Red, upregulated; green, downregulated.\
**Abbreviations:** FC, fold change; HCC, hepatocellular carcinoma.](cmar-11-877Fig6){#f6-cmar-11-877}

![Kaplan--Meier analysis to display the correlation of differentially expressed lncRNAs (**A**), miRNAs (**B**), and genes (**C**) with overall survival outcomes for patients with HBV-related HCC.\
**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](cmar-11-877Fig7){#f7-cmar-11-877}

![Kaplan--Meier analysis to display the correlation of differentially expressed genes with recurrence-free survival outcomes for patients with HBV-related HCC.\
**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](cmar-11-877Fig8){#f8-cmar-11-877}

###### 

Differentially expressed genes, miRNAs, and lncRNAs

  Symbol    LogFC    FDR         Symbol               LogFC   FDR         Symbol          LogFC   FDR
  --------- -------- ----------- -------------------- ------- ----------- --------------- ------- -----------
                                                                                                  
  *CDC6*    1.05     2.01E--03   *hsa-miR-215-3p*     29.41   3.08E--06   *LINC01662*     4.62    1.21E--07
  *CCNE1*   1.02     1.22E--02   *hsa-miR-301b*       3.80    8.46E--11   *DSCR8*         4.49    1.73E--17
  *CDK1*    1.04     2.02E--03   *hsa-miR-483-3p*     3.42    3.40E--09   *LINC01976*     4.30    7.43E--06
  *E2F2*    1.03     7.83E--03   *hsa-miR-410-3p*     3.25    1.76E--08   *LINC00632*     3.70    8.51E--13
  *BUB1*    1.11     6.22E--04   *hsa-miR-7974*       3.25    3.05E--08   *DSCR4*         3.63    2.03E--12
  *CCNB1*   1.03     2.17E--03   *hsa-miR-483-5p*     3.22    2.62E--08   *LINC02089*     3.50    9.85E--05
  *SFN*     1.54     4.46E--06   *hsa-miR-200c-3p*    3.17    4.31E--08   *MIR2052HG*     3.34    4.32E--11
  *GNG4*    1.48     6.54E--05   *hsa-miR-183-5p*     3.11    6.10E--08   *PRNT*          2.54    1.17E--03
  *UBE2C*   1.23     2.15E--04   *hsa-miR-1910-5p*    3.09    4.44E--04   *LINC00346*     2.02    3.33E--05
  *GNGT1*   2.04     1.49E--05   *hsa-miR-493-5p*     3.08    8.66E--08   *FAM182B*       1.30    1.04E--02
  *KIF4A*   1.15     5.96E--04   *hsa-miR-139-5p*     −2.22   1.49E--04   *PACRG-AS3*     −1.24   2.72E--02
  *GNG13*   1.40     1.87E--02   *hsa-miR-30c-2-3p*   −1.59   1.04E--02   *LINC01558*     −1.59   1.17E--03
  *PF4*     −1.36    2.03E--02   *hsa-miR-378i*       −1.54   1.32E--02   *LINC02312*     −1.60   1.47E--03
  *IL-6*    −1.04    2.94E--02   *hsa-miR-199a-5p*    −1.45   2.11E--02   *LINC02453*     −1.74   3.36E--04
  *CXCR1*   −1.056   1.64E--02   *hsa-miR-30a-5p*     −1.45   2.16E--02   *LILRB1-AS1*    −1.87   0.013104
  *INS*     −3.6     9.75E--11   *hsa-miR-125b-5p*    −1.43   2.29E--02   *LINC01561*     −2.05   7.28E--05
  *RD3L*    −3.16    2.70E--10   *hsa-miR-378d*       −1.43   2.43E--02   *LINC01550*     −2.09   1.89E--05
  *VGLL1*   −2.96    4.88E--06   *hsa-miR-10a-5p*     −1.41   2.62E--02   *LINC01620*     −2.16   2.77E--05
  *TH*      −2.85    7.02E--15   *hsa-miR-133a-3p*    −1.38   3.15E--02   *LINC01554*     −2.19   5.61E--06
  *CLDN8*   −2.83    3.13E--06   *hsa-miR-101-3p*     −1.37   3.12E--02   *B3GALT5-AS1*   −2.31   3.83E--06

**Abbreviations:** FC, fold change; FDR, false discovery rate.

###### 

GO enrichment for differentially expressed genes using the DAVID database

  Category                                    Term                               FDR                                                                                                                                                                                                                                                                                                                                                                    Genes
  ------------------------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Up                                          GO:0007049\~cell cycle             4.24E--10                                                                                                                                                                                                                                                                                                                                                              *E2F1, KIF23, E2F2, KIFC1, XRCC2, E2F7, E2F8, MAEL, PKMYT1, TTK, PTTG1, AURKB, GTSE1, KIF2C, CCNE1, CDCA8, CDC45, CDCA2, PIWIL3, CDCA5, CDC6, CDK1, EGFL6, MND1, PBK, HMGA2, UBE2C, PRDM9, BUB1B, ERN2, NEK2, ANLN, CEP55, SPC24, SPC25, NCAPH, DUSP13, HJURP, NCAPG, CENPA, BUB1, FBXO43, SKA3, SKA1, TRIP13, EXO1, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, CDKN3, CDC25C, CDC25A, GSG2, CCNB1, CCNB2, TEX11*
  GO:0022402\~cell cycle process              1.13E--11                          *KIF23, E2F1, KIFC1, XRCC2, MAEL, PKMYT1, TTK, AURKB, PTTG1, GTSE1, CCNE1, KIF2C, CDCA8, CDCA2, PIWIL3, CDCA5, CDC6, CDK1, MND1, PBK, UBE2C, HMGA2, PRDM9, BUB1B, ERN2, NEK2, ANLN, CEP55, SPC24, SPC25, NCAPH, DUSP13, CENPA, NCAPG, FBXO43, BUB1, SKA3, SKA1, TRIP13, EXO1, DLGAP5, KIF18A, NUF2, NDC80, BIRC5, CDC20, CDC25C, CDKN3, CDC25A, CCNB1, CCNB2, TEX11*   
  GO:0022403\~cell cycle phase                1.74E--15                          *E2F1, KIF23, KIFC1, XRCC2, NEK2, MAEL, TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, GTSE1, SPC24, CCNE1, KIF2C, SPC25, NCAPH, CDCA8, DUSP13, NCAPG, BUB1, FBXO43, CDCA2, SKA3, PIWIL3, SKA1, CDCA5, TRIP13, EXO1, CDK1, CDC6, DLGAP5, NUF2, KIF18A, MND1, CDC20, BIRC5, NDC80, PBK, HMGA2, CDKN3, CDC25C, UBE2C, CDC25A, CCNB1, PRDM9, CCNB2, BUB1B, TEX11*                
  GO:0000279\~M phase                         3.28E--16                          *KIF23, KIFC1, XRCC2, NEK2, MAEL, TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, SPC24, KIF2C, SPC25, NCAPH, CDCA8, DUSP13, NCAPG, BUB1, FBXO43, CDCA2, SKA3, PIWIL3, SKA1, CDCA5, TRIP13, EXO1, CDK1, CDC6, DLGAP5, NUF2, KIF18A, MND1, CDC20, BIRC5, NDC80, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, PRDM9, CCNB2, BUB1B, TEX11*                                           
  GO:0000278\~mitotic cell cycle              2.13E--11                          *E2F1, KIF23, KIFC1, NEK2, TTK, PKMYT1, ANLN, PTTG1, CEP55, AURKB, GTSE1, SPC24, CCNE1, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, CENPA, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, CDC20, BIRC5, NDC80, PBK, HMGA2, CDKN3, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                
  GO:0007067\~mitosis                         6.55E--14                          *KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                                                       
  GO:0000280\~nuclear division                6.55E--14                          *KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                                                       
  GO:0000087\~M phase of mitotic cell cycle   9.83E--14                          *KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                                                       
  GO:0048285\~organelle fission               1.97E--13                          *KIF23, KIFC1, NEK2, PKMYT1, ANLN, CEP55, AURKB, PTTG1, SPC24, KIF2C, SPC25, CDCA8, NCAPH, NCAPG, BUB1, CDCA2, SKA3, SKA1, CDCA5, CDK1, CDC6, DLGAP5, NUF2, KIF18A, BIRC5, NDC80, CDC20, PBK, HMGA2, CDC25C, UBE2C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                                                       
  GO:0051301\~cell division                   2.47E--08                          *KIF23, KIFC1, NEK2, ANLN, CEP55, AURKB, PTTG1, SPC24, CCNE1, SPC25, CDCA8, NCAPH, NCAPG, CDCA2, BUB1, SKA3, POU3F2, SKA1, CDCA5, CDK1, CDC6, NUF2, BIRC5, NDC80, CDC20, HMGA2, UBE2C, CDC25C, CDC25A, CCNB1, CCNB2, BUB1B*                                                                                                                                            
  Down                                        GO:0007267\~cell--cell signaling   1.82E--07                                                                                                                                                                                                                                                                                                                                                              *EDN3, GABRB3, FCRL2, VIPR1, VIPR2, GDNF, WNT2, KCNQ5, WISP2, SLC1A2, GRIN2B, CHRNA4, EFNB3, NPBWR1, IL26, NRXN1, NTSR1, IL22, SIGLEC6, GRM7, WNT9A, DRD1, GRAP, OXT, DRD5, TH, MME, RIMS1, CCL24, INS, CCL21, PRIMA1, BMP3, IL6, PLP1, NOS1, NTF3, DLGAP2, GABRA5, NPY5R, KCNK3, CCL17, WNT7B, CXCL14, PNOC, GRIA1, NTRK2, ADRA1A, SLC5A7, WNT7A, IL2, HTR2A*
  GO:0006952\~defense response                2.83E--07                          *KLRC4, KLRC2, KLRC3, CXCR1, CFP, GRIN2B, HAMP, RNASE7, IFNG, XCR1, NLRP7, CAMP, PRG2, PSG3, IL22, NCR1, NCR3, CCR9, PROK2, PSG8, PPBP, CD40LG, GRM7, DEFA3, PLA2G2D, CTSG, NGF, KIR3DL2, CLEC1B, C7, DRD1, CCK, CCL24, AZU1, FCN3, INS, CCL21, FCN2, CNR2, SFTPD, IL1RAPL2, SELP, IL6, IL5, IL1RL1, GABRA5, CCL19, CD5L, STAB2, S100A12, CCL17, MPO, SELE*            
  GO:0044057\~regulation of system process    3.67E--05                          *BMP10, EDN3, DRD1, CCK, ERBB4, MYL3, EDN2, DRD5, OXT, TH, GDNF, DES, GRIN2B, INS, IFNG, LGI1, ARC, GNAO1, NOS1, NTF3, NPY1R, NPY5R, PROK2, TNNT3, CHRM2, NTRK2, TBXA2R, AVPR1A, IL2, HTR2A, NGF*                                                                                                                                                                      
  GO:0007268\~synaptic transmission           1.17E--04                          *DRD1, GABRB3, DRD5, OXT, TH, VIPR1, RIMS1, WNT2, KCNQ5, SLC1A2, GRIN2B, CHRNA4, PRIMA1, PLP1, NOS1, NTF3, DLGAP2, NPBWR1, GABRA5, NRXN1, NTSR1, NPY5R, KCNK3, PNOC, GRIA1, GRM7, SLC5A7, WNT7A, HTR2A*                                                                                                                                                                
  GO:0051046\~regulation of secretion         1.79E--03                          *EDN3, IL6, EDN2, OXT, FGF23, NPY1R, GDNF, NPY5R, GCK, GRIN2B, CD40LG, INS, GRM7, IFNG, NTRK2, AVPR1A, CHRNA4, TRPV6, IL2, HTR2A, NGF*                                                                                                                                                                                                                                 
  GO:0006935ĉhemotaxis                        3.12E--03                          *EDN3, IL6, EDN2, CXCR1, CCL19, PF4, CCL17, CCR9, AZU1, CCL24, PROK2, PPBP, CXCL14, CCL21, IFNG, SFTPD, XCR1, LECT2*                                                                                                                                                                                                                                                   
  GO:0042742\~defense response to bacterium   8.64E--03                          *SELP, IL6, CAMP, PRG2, STAB2, S100A12, AZU1, CFP, PPBP, HAMP, RNASE7, IFNG, DEFA3, CTSG*                                                                                                                                                                                                                                                                              
  GO:0050900\~leukocyte migration             9.20E--03                          *AZU1, EDN3, SELP, IL6, EDN2, IFNG, ELANE, SFTPD, PF4, SELE*                                                                                                                                                                                                                                                                                                           
  GO:0022610\~biological adhesion             1.39E--02                          *CLDN8, CLSTN2, OPCML, DSCAML1, CLDN10, L1CAM, MEGF10, WISP2, SRPX, TNR, DPT, DSCAM, TECTA, SELP, MAG, HAPLN4, RET, CDHR1, PCDH11X, CDHR2, IGFALS, SIGLEC11, AJAP1, STAB2, NRXN1, PCDH19, CTNNA3, CLEC4M, DSG4, LYVE1, FREM3, HEPACAM, SIGLEC6, FREM2, CD40LG, DSG1, CDH19, ITGAD, CNTN3, SELE, COL20A1, IL2*                                                          
  GO:0006954înflammatory response             2.80E--02                          *SELP, C7, IL6, IL5, CXCR1, CCL19, IL22, S100A12, CCL17, NCR3, AZU1, CFP, CCL24, PROK2, FCN3, CD40LG, INS, CCL21, FCN2, CNR2, XCR1, SELE, PLA2G2D, NGF*                                                                                                                                                                                                                

**Note:** Top 10 terms were listed.

**Abbreviations:** DAVID, Database for Annotation, Visualization and Integrated Discovery; FDR, false discovery rate; GO, Gene Ontology.

###### 

KEGG pathway enrichment for differentially expressed genes using the DAVID database

  Category                                            Term                          FDR                                                                                                                                                                                              Genes
  --------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                     
  Up                                                  hsa04110:cell cycle           2.16E--08                                                                                                                                                                                        *E2F1, E2F2, CDK1, CDC6, PKMYT1, TTK, CDC20, PTTG1, SFN, CDC25C, CDC25A, CCNB1, CCNE1, CDC45, CCNB2, BUB1, BUB1B*
  hsa04080:neuroactive ligand--receptor interaction   2.66E--04                     *GABRD, CGA, GABRG2, GABRA2, GABRA3, GLRA2, LEP, GRM4, SSTR5, KISS1R, HTR1B, GABRR1, GRID2, NPFFR2, TAAR1, HTR1D, GLP1R*                                                                         
  hsa04115:p53 signaling pathway                      2.08E--02                     *CCNB1, CDK1, CCNE1, CCNB2, SFN, GTSE1*                                                                                                                                                          
  hsa04060:cytokine--cytokine receptor interaction    2.69E--02                     *LEP, CCR8, CCL20, GDF5, EGF, BMP7, CCL7, IL11, CCL26*                                                                                                                                           
  hsa04062:chemokine signaling pathway                2.73E--02                     *CCR8, GNGT1, CCL20, GNG13, GNG4, CCL7, CCL26*                                                                                                                                                   
  hsa00604:glycosphingolipid biosynthesis             2.99E--02                     *ST6GALNAC5, B4GALNT1*                                                                                                                                                                           
  hsa04512:ECM--receptor interaction                  3.14E--02                     *IBSP, COMP, COL2A1, COL11A1*                                                                                                                                                                    
  hsa04350:TGF-beta signaling pathway                 3.33E--02                     *COMP, GDF5, BMP7, PITX2*                                                                                                                                                                        
  hsa03320:PPAR signaling pathway                     4.83E--02                     *LPL, MMP1, FABP6*                                                                                                                                                                               
  Down                                                hsa00830:retinol metabolism   8.15E--10                                                                                                                                                                                        *CYP3A4, CYP1A1, CYP2B6, CYP2C8, ADH1B, CYP26A1, ADH7, CYP1A2, CYP3A43, CYP2A13, CYP4A11, UGT2B17, CYP4A22, LRAT, ADH4, CYP2A6, CYP2A7, RDH16*
  hsa00982:drug metabolism                            2.89E--05                     *CYP3A4, CYP2B6, CYP2C8, ADH1B, ADH7, CYP1A2, CYP2E1, GSTM5, CYP3A43, CYP2A13, UGT2B17, ADH4, CYP2A6, CYP2A7*                                                                                    
  hsa04080:neuroactive ligand--receptor interaction   1.79E--04                     *GPR83, DRD1, GABRB3, DRD5, PTH1R, PRSS1, VIPR1, VIPR2, GCGR, GRIN2B, CNR2, GLP2R, GABRP, NPBWR1, GABRA5, NPY1R, NTSR1, NPY5R, GRIA1, CHRM2, GRM7, PTGDR, TBXA2R, AVPR1A, ADRA1A, CTSG, HTR2A*   
  hsa04060:cytokine--cytokine receptor interaction    2.07E--04                     *CXCR1, CNTFR, PF4, PF4V1, CCL24, CXCR5, CCL21, IFNG, XCR1, AMHR2, IL6, IL5, FLT3, TNFRSF13B, TNFRSF13C, IL26, CCL19, IL22, CCL17, CCR9, TSLP, CXCL14, PPBP, CD40LG, IL5RA, NGFR, IL2*           
  hsa00980:metabolism of xenobiotics by CYP/CYP450    3.64E--04                     *CYP3A43, CYP3A4, UGT2B17, CYP1A1, CYP2B6, ADH4, CYP2C8, ADH1B, ADH7, CYP2E1, CYP1A2, GSTM5*                                                                                                     
  hsa00232:caffeine metabolism                        1.50E--03                     *CYP2A13, NAT2, CYP2A6, CYP2A7, CYP1A2*                                                                                                                                                          
  hsa00983:drug metabolism                            2.10E--02                     *CYP3A43, CYP3A4, CYP2A13, UGT2B17, NAT2, UPP2, CYP2A6, CYP2A7*                                                                                                                                  
  hsa04340:Hedgehog signaling pathway                 2.00E--02                     *WNT2, WNT1, WNT10A, WNT7B, WNT9A, HHIP, GAS1, WNT7A, BMP5*                                                                                                                                      

**Abbreviations:** DAVID, Database for Annotation, Visualization and Integrated Discovery; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Topological features for each protein in PPI network

  Gene       Degree   Gene       CC       Gene        BC       Gene       APL      Overlapped   Expression
  ---------- -------- ---------- -------- ----------- -------- ---------- -------- ------------ ------------
                                                                                                
  *GNGT1*    87       *IL6*      0.3179   *IL6*       0.2515   *IL6*      3.1461   CCNB1        Up
  *GNG13*    85       *CHRM2*    0.2989   *UBE2C*     0.1845   *CHRM2*    3.3455   CDK1         Up
  *GNG4*     64       *SH3GL2*   0.2959   *NGF*       0.1695   *SH3GL2*   3.3792   GNG4         Up
  *CDK1*     56       *EGF*      0.2947   *TH*        0.1586   *EGF*      3.3933   UBE2C        Up
  *CCNB1*    52       *ESR1*     0.2890   *GNGT1*     0.1413   *ESR1*     3.4607   GNGT1        Up
  *CDC20*    48       *CCL20*    0.2848   *FOSB*      0.1406   *CCL20*    3.5112   KIF4A        Up
  *BUB1*     48       *GNGT1*    0.2846   *MMP1*      0.1388   *GNGT1*    3.5140   PF4          Down
  *CCNB2*    47       *GNG13*    0.2823   *CHRM2*     0.1186   *GNG13*    3.5421   GNG13        Up
  *KIF2C*    47       *INS*      0.2821   *SH3GL2*    0.1164   *INS*      3.5449                
  *PMCH*     45       *UBE2C*    0.2808   *EGF*       0.1106   *UBE2C*    3.5618                
  *AURKB*    44       *PF4*      0.2803   *E2F1*      0.1043   *PF4*      3.5674                
  *CENPA*    43       *PTHLH*    0.2786   *ESR1*      0.1013   *PTHLH*    3.5899                
  *KIF20A*   39       *GNG4*     0.2777   *GNG13*     0.0956   *GNG4*     3.6011                
  *BUB1B*    39       *NGF*      0.2766   *INS*       0.0904   *NGF*      3.6152                
  *NCAPG*    38       *GNAO1*    0.2728   *KIF4A*     0.0670   *GNAO1*    3.6657                
  *CDCA8*    38       *KIF4A*    0.2722   *PTHLH*     0.0669   *KIF4A*    3.6742                
  *GCGR*     37       *PPBP*     0.2713   *CDK1*      0.0637   *PPBP*     3.6854                
  *NPSR1*    37       *GNA14*    0.2709   *ACAN*      0.0632   *GNA14*    3.6910                
  *BIRC5*    37       *LEP*      0.2707   *CCL20*     0.0620   *LEP*      3.6938                
  *TTK*      37       *TERT*     0.2707   *GNAO1*     0.0593   *TERT*     3.6938                
  *NDC80*    37       *GNAZ*     0.2669   *CAMK2B*    0.0547   *GNAZ*     3.7472                
  *DLGAP5*   36       *NGFR*     0.2661   *LPL*       0.0444   *NGFR*     3.7584                
  *UBE2C*    35       *SYT9*     0.2655   *CYP19A1*   0.0430   *SYT9*     3.7669                
  *CDC45*    35       *E2F1*     0.2651   *CCNB1*     0.0417   *E2F1*     3.7725                
  *PF4*      34       *HTR1B*    0.2645   *GNG4*      0.0402   *HTR1B*    3.7809                
  *KIF4A*    34       *CDK1*     0.2639   *CHRNA1*    0.0394   *CDK1*     3.7893                
  *PBK*      34       *PMCH*     0.2639   *PF4*       0.0393   *PMCH*     3.7893                
  *KIF23*    34       *HTR1D*    0.2639   *RHO*       0.0370   *HTR1D*    3.7893                
  *CXCR1*    33       *CCNB1*    0.2625   *NOS1*      0.0353   *CCNB1*    3.8090                
  *XCR1*     33       *CXCR1*    0.2597   *NGFR*      0.0348   *CXCR1*    3.8511                

**Note:** Top 30 genes were listed.

**Abbreviations:** APL, average path length; BC, betweenness centrality; CC, closeness centrality; PPI, protein--protein interaction.

###### 

BinGO enrichment for genes in modules

  Module                                                               Description                                            FDR                                                                                                                                                                                                                                                                                                     Genes in test set
  -------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                                                      
  M1                                                                   Mitotic cell cycle                                     9.74E--37                                                                                                                                                                                                                                                                                               *CDCA5\|BUB1B\|CDCA8\|NCAPG\|TTK\|CENPA\|SKA1\|AUR KB\|CDC20\|CCNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BU B1\|CEP55\|DLGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18 A\|CDK1\|BIRC5\|KIF2C\|SPC24\|CDKN3\|SPC25*
  Nuclear division                                                     9.74E--37                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|SKA1\|AURKB\|CDC20\|C CNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP55\|D LGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1\|BIRC 5\|KIF2C\|SPC24\|SPC25*                                                                                                                     
  Mitosis                                                              9.74E--37                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|SKA1\|AURKB\|CDC20\|C CNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP55\|D LGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1\|BIRC 5\|KIF2C\|SPC24\|SPC25*                                                                                                                     
  M phase of mitotic cell cycle                                        1.65E--36                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|SKA1\|AURKB\|CDC20\|C CNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP55\|D LGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1\|BIRC 5\|KIF2C\|SPC24\|SPC25*                                                                                                                     
  Organelle fission                                                    1.65E--36                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|SKA1\|AURKB\|CDC20\|C CNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP55\|D LGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1\|BIRC 5\|KIF2C\|SPC24\|SPC25*                                                                                                                     
  M phase                                                              2.75E--36                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|TTK\|SKA1\|AURKB\|CDC 20\|CCNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP 55\|DLGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1 \|BIRC5\|KIF2C\|TRIP13\|SPC24\|SPC25*                                                                                                        
  Cell cycle phase                                                     1.03E--35                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|TTK\|SKA1\|AURKB\|CDC 20\|CCNB2\|CCNB1\|PTTG1\|NUF2\|PBK\|NEK2\|BUB1\|CEP 55\|DLGAP5\|UBE2C\|KIF23\|NDC80\|ANLN\|KIF18A\|CDK1 \|BIRC5\|KIF2C\|TRIP13\|SPC24\|CDKN3\|SPC25*                                                                                                 
  Cell cycle process                                                   5.27E--34                                              *CDCA5\|BUB1B\|CDCA8\|NCAPG\|TTK\|CENPA\|SK A1\|AURKB\|CDC20\|CCNB2\|CCNB1\|PTTG1\|NUF 2\|PBK\|NEK2\|BUB1\|CEP55\|DLGAP5\|UBE2C\|KIF 23\|NDC80\|ANLN\|KIF18A\|CDK1\|BIRC5\|KIF2C\| TRIP13\|SPC24\|CDKN3\|SPC25*                                                                                         
  Cell cycle                                                           7.78E--34                                              *CDCA5\|HJURP\|BUB1B\|CDCA8\|NCAPG\|TTK\|CENPA\|SK A1\|AURKB\|CDC20\|CCNB2\|CCNB1\|CDC45\|PTTG1\|NU F2\|PBK\|NEK2\|BUB1\|CEP55\|DLGAP5\|UBE2C\|KIF23\|ND C80\|ANLN\|KIF18A\|CDK1\|BIRC5\|KIF2C\|TRIP13\|SPC24\| CDKN3\|SPC25*                                                                           
  Cell division                                                        8.53E--28                                              *UBE2C\|CDCA5\|BUB1B\|CDCA8\|NCAPG\|KIF23\|SKA1\|A URKB\|NDC80\|CDC20\|CCNB2\|ANLN\|CCNB1\|PTTG1\| NUF2\|CDK1\|BIRC5\|NEK2\|KIF2C\|BUB1\|CEP55\|SPC24 \|SPC25*                                                                                                                                          
  M2                                                                   G-protein-coupled receptor protein signaling pathway   4.81E--36                                                                                                                                                                                                                                                                                               *NPFFR2\|CHRM2\|PMCH\|CXCR5\|HTR2A\|ADRA1A\|GNGT 1\|GNA14\|GRM4\|CXCR1\|CNR2\|TBXA2R\|NPBWR1\|KISS 1R\|CCR9\|CCR8\|PROK2\|TAC3\|NTSR1\|P2RY12\|XCR1\|ED N2\|NPY5R\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\|AVPR1A\| SSTR5\|GNG13\|PPYR1\|PNOC*
  Cell surface receptor-linked signaling pathway                       8.03E--26                                              *NPFFR2\|CHRM2\|PMCH\|CXCR5\|HTR2A\|ADRA1A\|GNGT 1\|GNA14\|GRM4\|CXCR1\|CNR2\|TBXA2R\|NPBWR1\|KISS 1R\|CCR9\|CCR8\|PROK2\|TAC3\|NTSR1\|P2RY12\|XCR1\|ED N2\|NPY5R\|EDN3\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\|A VPR1A\|SSTR5\|GNG13\|PPYR1\|PNOC\|PF4*                                                       
  Signaling                                                            6.64E--24                                              *NPFFR2\|CHRM2\|PMCH\|CXCR5\|OXT\|HTR2A\|ADRA1A \|GNGT1\|GNA14\|GRM4\|CXCR1\|CNR2\|GRM7\|TBXA2R\| GNG4\|NPBWR1\|KISS1R\|CCR9\|CCR8\|PROK2\|TAC3\|CCL 19\|NTSR1\|P2RY12\|XCR1\|EDN2\|NPY5R\|CCL21\|EDN3\| CCL20\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\|AVPR1A\|SST R5\|GNG13\|APLN\|PPYR1\|PNOC\|GNRH2\|PF4*   
  Behavior                                                             1.44E--23                                              *PMCH\|OXT\|HTR2A\|GRM4\|CXCR1\|CNR2\|KISS1R\|CCR 9\|CCR8\|PROK2\|CCL19\|NTSR1\|XCR1\|EDN2\|NPY5R\|C CL21\|EDN3\|CCL20\|NPY1R\|HTR1B\|CCK\|AVPR1A\|PPBP \|PPYR1\|PF4*                                                                                                                                   
  Signaling pathway                                                    3.33E--20                                              *NPFFR2\|CHRM2\|PMCH\|CXCR5\|HTR2A\|ADRA1A\|GNGT 1\|GNA14\|GRM4\|CXCR1\|CNR2\|TBXA2R\|GNG4\|NPBW R1\|KISS1R\|CCR9\|CCR8\|PROK2\|TAC3\|NTSR1\|P2RY12\|X CR1\|EDN2\|NPY5R\|EDN3\|GCGR\|HTR1D\|NPY1R\|HTR1B \|CCK\|AVPR1A\|SSTR5\|GNG13\|PPYR1\|PNOC\|PF4*                                                 
  Signaling process                                                    2.04E--17                                              *CHRM2\|PMCH\|OXT\|HTR2A\|ADRA1A\|GNGT1\|GNA14\| GRM4\|CNR2\|GRM7\|NPBWR1\|KISS1R\|PROK2\|CCL19\|N TSR1\|P2RY12\|XCR1\|EDN2\|NPY5R\|CCL21\|EDN3\|CCL2 0\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\|AVPR1A\|SSTR5\|G NG13\|APLN\|PNOC\|GNRH2\|PF4*                                                                 
  Signal transmission                                                  2.04E--17                                              *CHRM2\|PMCH\|OXT\|HTR2A\|ADRA1A\|GNGT1\|GNA14\| GRM4\|CNR2\|GRM7\|NPBWR1\|KISS1R\|PROK2\|CCL19\|N TSR1\|P2RY12\|XCR1\|EDN2\|NPY5R\|CCL21\|EDN3\|CCL2 0\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\|AVPR1A\|SSTR5\|G NG13\|APLN\|PNOC\|GNRH2\|PF4*                                                                 
  Signal transduction                                                  1.43E--14                                              *CHRM2\|PMCH\|OXT\|HTR2A\|ADRA1A\|GNGT1\|GNA14\| GRM4\|CNR2\|KISS1R\|PROK2\|CCL19\|P2RY12\|XCR1\|ED N2\|CCL21\|EDN3\|CCL20\|GCGR\|HTR1D\|NPY1R\|HTR1B\| CCK\|AVPR1A\|SSTR5\|GNG13\|APLN\|PNOC\|GNRH2\|PF4*                                                                                              
  Response to stimulus                                                 2.05E--12                                              *NPFFR2\|CHRM2\|PMCH\|OXT\|HTR2A\|ADRA1A\|GNGT1\| GRM4\|CXCR1\|CNR2\|GRM7\|GNG4\|KISS1R\|CCR9\|CCR8 \|PROK2\|CCL19\|NTSR1\|P2RY12\|XCR1\|EDN2\|NPY5R\|C CL21\|EDN3\|CCL20\|GCGR\|HTR1D\|NPY1R\|HTR1B\|CCK\| AVPR1A\|PPBP\|GNG13\|APLN\|PPYR1\|PF4*                                                      
  Response to chemical stimulus                                        2.96E--11                                              *XCR1\|EDN2\|CCL21\|EDN3\|CCL20\|GCGR\|HTR1D\|NP Y1R\|HTR1B\|OXT\|CCK\|HTR2A\|AVPR1A\|PPBP\|ADRA1A \|GNG13\|CXCR1\|CNR2\|GNG4\|CCR9\|CCR8\|PROK2\|CC L19\|PF4*                                                                                                                                          
  M3                                                                   Cyclic-nucleotide-mediated signaling                   6.43E--09                                                                                                                                                                                                                                                                                               *GLP1R\|VIPR1\|GLP2R\|PTH1R\|DRD1\|PTHLH\|DRD5*
  G-protein-coupled receptor protein signaling pathway                 2.93E--08                                              *VIPR1\|GPR15\|GLP2R\|PTH1R\|DRD1\|TAAR1\|PTHLH\|DR D5\|PTGDR*                                                                                                                                                                                                                                          
  Second messenger-mediated signaling                                  9.78E--08                                              *GLP1R\|VIPR1\|GLP2R\|PTH1R\|DRD1\|PTHLH\|DRD5*                                                                                                                                                                                                                                                         
  G-protein signaling, coupled to cyclic nucleotide second messenger   9.78E--08                                              *VIPR1\|GLP2R\|PTH1R\|DRD1\|PTHLH\|DRD5*                                                                                                                                                                                                                                                                
  Cell surface receptor-linked signaling pathway                       2.27E--05                                              *VIPR1\|GPR15\|GLP2R\|PTH1R\|DRD1\|TAAR1\|PTHLH\|DR D5\|PTGDR*                                                                                                                                                                                                                                          
  Signaling                                                            3.01E--05                                              *GLP1R\|VIPR1\|GPR15\|VIPR2\|GLP2R\|PTH1R\|DRD1\|CGA\|T AAR1\|PTHLH\|DRD5\|PTGDR*                                                                                                                                                                                                                       
  Signaling pathway                                                    5.37E--05                                              *GLP1R\|VIPR1\|GPR15\|GLP2R\|PTH1R\|DRD1\|TAAR1\|PTH LH\|DRD5\|PTGDR*                                                                                                                                                                                                                                   
  Intracellular signal transduction                                    8.25E--05                                              *GLP1R\|VIPR1\|GLP2R\|PTH1R\|DRD1\|PTHLH\|DRD5*                                                                                                                                                                                                                                                         
  Cell--cell signaling                                                 1.41E--04                                              *VIPR1\|VIPR2\|DRD1\|CGA\|PTHLH\|DRD5*                                                                                                                                                                                                                                                                  
  Signal transduction                                                  1.59E--04                                              *GLP1R\|VIPR1\|VIPR2\|GLP2R\|PTH1R\|DRD1\|CGA\|PTHLH \|DRD5*                                                                                                                                                                                                                                            
  Signaling process                                                    4.51E--04                                              *GLP1R\|VIPR1\|VIPR2\|GLP2R\|PTH1R\|DRD1\|CGA\|PTHLH \|DRD5*                                                                                                                                                                                                                                            
  Cell communication                                                   7.10E--04                                              *VIPR1\|VIPR2\|DRD1\|CGA\|PTHLH\|DRD5*                                                                                                                                                                                                                                                                  
  M4                                                                   Drug metabolic process                                 3.44E--16                                                                                                                                                                                                                                                                                               *CYP2A6\|CYP2C8\|CYP2B6\|CYP1A2\|CYP1A1\|CYP2E1\|C YP3A4*
  Secondary metabolic process                                          4.89E--11                                              *CYP26A1\|CYP2A6\|CYP1A2\|CYP1A1\|CYP2E1\|CYP3A4*                                                                                                                                                                                                                                                       
  Oxidation reduction                                                  2.91E--10                                              *CYP26A1\|CYP2A6\|CYP2C8\|CYP2B6\|CYP4A11\|CYP1A2\|C YP1A1\|CYP2E1\|CYP3A4*                                                                                                                                                                                                                             
  Steroid metabolic process                                            4.84E--10                                              *CYP2A6\|CYP2B6\|CYP1A2\|CYP1A1\|UGT2B17\|CYP2E1\| CYP3A4*                                                                                                                                                                                                                                              
  Lipid metabolic process                                              1.79E--09                                              *CYP26A1\|CYP2A6\|CYP2B6\|CYP4A11\|CYP1A2\|CYP1A1\| UGT2B17\|CYP2E1\|CYP3A4*                                                                                                                                                                                                                            
  Response to drug                                                     1.12E--07                                              *CYP2A6\|CYP2C8\|CYP2B6\|CYP1A2\|CYP1A1\|CYP3A4*                                                                                                                                                                                                                                                        
  Cellular catabolic process                                           2.17E--06                                              *CYP26A1\|CYP2A6\|CYP2C8\|CYP2B6\|CYP1A2\|CYP1A1\| CYP3A4*                                                                                                                                                                                                                                              
  Small molecule metabolic process                                     3.78E--06                                              *CYP26A1\|CYP2A6\|CYP2C8\|CYP2B6\|CYP4A11\|CYP1A2\| CYP1A1\|CYP3A4*                                                                                                                                                                                                                                     
  Cellular lipid metabolic process                                     6.87E--06                                              *CYP26A1\|CYP4A11\|CYP1A2\|CYP1A1\|CYP2E1\|CYP3A4*                                                                                                                                                                                                                                                      
  Catabolic process                                                    9.30E--06                                              *CYP26A1\|CYP2A6\|CYP2C8\|CYP2B6\|CYP1A2\|CYP1A1\| CYP3A4*                                                                                                                                                                                                                                              

**Abbreviation:** FDR, false discovery rate.

###### 

KEGG pathways for genes in ceRNA network

  Term                                                *P*-value   Genes
  --------------------------------------------------- ----------- ---------------------------------------------
                                                                  
  hsa04110:cell cycle                                 2.85E--06   *CCNB1, E2F2, CDK1, CCNE1, CDC6, BUB1, SFN*
  hsa04115:p53 signaling pathway                      0.001617    *CCNB1, CDK1, CCNE1, SFN*
  hsa04080:neuroactive ligand--receptor interaction   0.04606     *GPR83, GABRB3*
  hsa05200:pathways in cancer                         0.046995    *E2F2, CCNE1*

**Abbreviation:** KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Cox regression analysis to screen survival-related genes

  ID                  Overall survival   Recurrence-free survival           
  ------------------- ------------------ -------------------------- ------- --------
                                                                            
  *E2F2*              1.24               0.049                      1.19    0.16
  *CDC6*              1.28               0.0372                     1.41    0.0099
  *CCNE1*             1.05               0.0456                     1.08    0.32
  *CDK1*              1.32               0.022                      1.48    0.0036
  *BUB1*              1.31               0.013                      1.37    0.0054
  *CCNB1*             1.4                0.014                      1.36    0.023
  *SFN*               1.22               0.0023                     1.19    0.0055
  *hsa-miR-10a-5p*    0.882              0.04                       0.854   0.27
  *hsa-miR-125b-5p*   0.835              0.019                      0.952   0.74
  *hsa-miR-133a-3p*   0.11               0.045                      0.879   0.39
  *hsa-miR-199a-5p*   0.986              0.88                       0.907   0.28
  *hsa-miR-30a-5p*    0.911              0.0452                     0.866   0.32
  *LINC00346*         1.67               0.0051                     0.99    0.85
  *DSCR4*             1.03               0.68                       0.994   0.95
  *FAM182B*           1.152              0.047                      0.84    0.19

###### 

Confirmation of expressions of crucial lncRNAs, miRNAs, and mRNAs using other datasets

  RNA type       Dataset          Symbol          Tumor (mean ± SD)   Control (mean ± SD)   *P*-value
  -------------- ---------------- --------------- ------------------- --------------------- -----------
                                                                                            
  lncRNA         GSE27462         *FAM182B*       75.834±27.913       71.793±23.127         0.8096
  *LINC00346*    124.665±28.955   72.848±14.226   0.01208                                   
  TCGA           *FAM182B*        3.403±1.255     2.539±0.944         0.081                 
  *LINC00346*    14.834±3.436     12.679±1.403    0.0397                                    
  miRNA          GSE69580         *miR-125b-5p*   39.384±23.416       355.428±82.423        0.000606
  *miR-10a-5p*   4.229±2.103      10.111±2.647    0.00507                                   
  TCGA           *miR-125b-5p*    8.962±1.092     10.203±0.352        4.09E--08             
  *miR-10a-5p*   13.607±1.198     14.779±0.472    4.89E--06                                 
  mRNA           GSE121248        *E2F2*          4.252±0.181         4.239±0.157           0.696
  *CDK1*         7.224±1.105      5.379±0.799     2.68793E--16                              
  *CCNE1*        7.056±1.032      6.415±0.216     0.00000344                                
  GSE94660       *E2F2*           0.83±0.443      0.0611±0.028        1.234E--07            
  *CDK1*         2.141±0.769      0.251±0.121     2.9E--10                                  
  *CCNE1*        1.412±0.669      0.242±0.129     9.01E--08                                 
  GSE25599       *E2F2*           0.769±0.496     0.302±0.255         0.01958               
  *CDK1*         5.116±2.925      1.152±0.923     0.005978                                  
  *CCNE1*        2.015±1.820      0.430±0.242     0.02254                                   
  TCGA           *E2F2*           5.612±1.296     2.959±1.076         0.000926              
  *CDK1*         8.018±1.428      4.579±1.266     0.00374                                   
  *CCNE1*        6.322±1.993      3.162±0.979     0.00193                                   

**Abbreviation:** TCGA, The Cancer Genome Atlas.
